Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,465,178

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

Zacks.com featured highlights include TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services

TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services are part of Zacks Screen of the Week article.

Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply

Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.

Sweta Killa headshot

5 Dividend Growth Stocks to Beat September Slump

Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.

Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics

Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business

According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.

Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?

Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Teladoc Health (TDOC) Ties Up to Upgrade RPM Care in Canada

Teladoc Health (TDOC) teams up with Cloud DX to bring its virtual care capabilities to the latter's platform and dispense advanced RPM solutions to the Canadian residents.

Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis

Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

What's in Store for Patterson Companies (PDCO) in Q1 Earnings?

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.

Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag

Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why Investors Should Retain Myriad Genetics (MYGN) Now

Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.

Is McKesson (MCK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?

Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass

Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Abbott (ABT) to Offer New Treatment Option for Chronic Pain

Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.